Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding specific share transactions rather than a financial performance report.
Material Changes
The filing discloses an increase in the notional allocation of GSK American Depositary Shares (ADSs) within the GSK 401K plan. This change resulted from the revaluation of the cash element of the notional investment held within the plan as of July 31, 2015.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly reports a specific transaction event.
Important Facts for Investors
- Transaction Date: The increase in notional allocation occurred on July 31, 2015, with notification on August 3, 2015.
- Share Price: The transaction was valued at $43.44 per ADS.
- Connected Person: The transaction involved Dr. K. Slaoui, identified as a connected person of Dr. M. Slaoui.
- Volume: The transaction involved 11 ADSs.
- Context: The change was driven by the revaluation of the cash element within the GSK 401K plan.